Our method shows its potential therapeutic use in CD through acting on multiple targets HSP90AA1 and FPR1, affecting multiple pathways NOD-like receptor signaling pathway and staphylococcus aureus infection pathway, and further affecting multiple CD mechanism genes IL6, TNF, NLRP3, NOD2, FPR2 and IL10. The gene discussed is FPR2; the disease is staphylococcus aureus infection.